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Autoimmune dysfunctions are the “bête noire” in a range of debilitating nephropathies.
Autoimmune-mediated damage to the kidneys can be triggered by autoantibodies
directed against specific proteins or renal structures, for example, the phospholipase A2
receptor or the glomerular basement membrane, resulting in glomerular diseases such
as primary membranous nephropathy or Goodpasture’s disease. Moreover, secondary
damage to the kidney can be part of the wide-reaching effects of systemic autoimmune
diseases such as vasculitis or systemic lupus erythematosus (SLE) – the latter counts
lupus nephritis among its most severe manifestations. Systemic autoimmune diseases
are characterized by non-organ-specific autoantibodies, directed for example against
neutrophil cytoplasmic antigens in systemic vasculitis and against double-stranded DNA
and nucleosomes in SLE. A large variety of innovative and highly specific and sensitive
autoantibody tests have been developed in the last years that are available to identify
autoimmune kidney diseases at an early stage. Thus, serological in vitro diagnostics
allow for appropriate interventional therapy in order to prevent disease progression often
resulting in need of dialysis and transplantation.
Keywords: autoantibodies, renal autoimmune diseases, anti-PLA2R, anti-THSD7A, anti-nucleosomes, anti-dsDNA,
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Introduction
Several autoantibodies have been characterized as associated with renal diseases with some of them
being possibly implicated in pathogenesis. Even if this causal relationship is not established, the
detection of autoantibodies has an important role in diagnosis and follow-up of these diseases (i.e.,
as a marker of response during treatment).
Among the renal diseases associated with autoantibodies, glomerular diseases are particularly
important. It is of note that glomerulopathies are rare, but often responsible for progression to
end-stage renal disease. Therefore, adequate and early diagnosis is essential in the management of
glomerular disease with influence on prognosis.
This paper will review the main aspects of four clinically relevant renal autoimmune dis-
eases – membranous nephropathy (MN), Goodpasture’s disease, lupus nephritis (LN), and anti-
neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV). The diseases may
be grouped according to their autoimmune response to either renal or ubiquitous antigens
(Table 1).
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TABLE 1 | Renal autoimmune diseases and associated autoantigens.
Disease Target antigen
Immune responses against renal antigens
Primary membranous nephropathy (pMN) PLA2R, THSD7A
Goodpasture’s disease NC1 domain of collagen type IV
Systemic immune responses against ubiquitous antigens associated with
renal inflammation
Lupus nephritis (LN) dsDNA, nucleosomes, C1q
ANCA-associated vasculitis (AAV) PR3, MPO
IgA nephropathy (IgAN) Galactose-deficient IgA1
Atypical hemolytic uremic syndrome (aHUS) Complement factor H
Membranoproliferative glomerulonephritis
(MPGN)
C3 convertase, C1q,
complement factor B and H
Immune Responses Against Renal
Antigens
Anti-PLA2R and Anti-THSD7A Autoantibodies in
Primary Membranous Nephropathy
Membranous nephropathy, one of the most frequent glomerular
diseases, is the major cause of nephrotic syndrome (1). It pre-
dominantly affects adults and the elderly. Although spontaneous
remission occurs in about one-third of patients, a similar number
of patients develop end-stage renal failure within 10 years.
The clinical picture and traditional laboratory tests give hints
toward the diagnosis in MN. Definitive diagnosis can only be
made after histological examination of kidney tissue obtained by
biopsy using different microscopy techniques (light, immunoflu-
orescence, and electron microscopy).
Nevertheless, it is important to know that there are exceptional
situations in which such diagnosis is not sufficiently clear, for
instance at earlier phases of the disease, or if the biopsy specimen
does not include adequate tissue for all mentioned microscopy
techniques, is contraindicated or not available.
Further obstacles in obtaining the correct diagnosis are due to
the etiology of MN. MN can be the primary disorder (pMN) or
it can be secondary to underlying systemic lupus erythematosus
(SLE), hepatitis B and C infection, malignancies, use of certain
medications, and several other etiologic agents. The differenti-
ation between both forms is important but can be challenging
at times. If the search of an underlying disease applying routine
laboratory markers is negative, doubts can persist and complicate
the management of the disease.
One of the most important discoveries in glomerular diseases
in the last decade was the understanding of the possible mech-
anisms of disease development by the identification of the M-
type phospholipase A2 receptor (PLA2R) as the target antigen of
autoantibodies in idiopathic MN (2).
Anti-PLA2R autoantibodies are highly specific for pMN and
are found in the serum of approx. 75% of pMN patients at time of
diagnosis. In patients with secondary MN or in healthy individu-
als, anti-PLA2R antibodies only occur rarely. The target antigen is
a type-1 transmembrane glycoprotein receptor that is expressed
on the surface of podocytes. Although the exact mechanisms
causing pMN are still not completely resolved, it is assumed that
upon binding of circulating autoantibodies to podocyte PLA2R,
subepithelial deposits are formed in situ, subsequently leading
to nephrotic syndrome including proteinuria after a cascade of
events.
For the determination of anti-PLA2R autoantibodies, two
standardized assays are available from EUROIMMUN that are
highly suitable for routine diagnostic purposes: a recombinant
cell-based indirect immunofluorescence test (RC-IIFT) and an
enzyme-linked immunosorbent assay (ELISA). RC-IIFT uses
the human cell line HEK293 overexpressing full-length human
PLA2R as substrate (3). The PLA2R-positive cells are arranged
in a biochip format in combination with control-transfected cells
in one incubation field (mosaic) [Anti-PLA2R IIFT (IgG)]. Using
this assay, anti-PLA2R antibodies were detected with maximal
specificity (100%) and with a sensitivity of 77% in a cohort of
275 biopsy-proven pMNpatients. In concordancewith the finding
that anti-PLA2R antibody concentrations decrease in patients
undergoing successful immunosuppressive therapy and can reach
undetectable level, a lower prevalence of 52% was found in a
cohort of pMN patients that included several patients under rit-
uximab treatment (3). For the accurate quantification of autoanti-
body concentrations, an ELISA based on the recombinantly pro-
duced extracellular domain of PLA2Rhas recently been developed
[Anti-PLA2R ELISA (IgG)] (4). In a large cohort of clinically well-
characterized patients, this assay revealed very high sensitivity
with respect to RC-IIFT (96.5%) at a set specificity of 99.9%.
The quantitative results of ELISA and RC-IIFT show a good
correlation (R2= 0.7491).
Detection of anti-PLA2R antibodies is crucial to discriminate
between patients with primary and secondary MN, as both forms
require different diagnostic approaches and treatment strategies.
Moreover, anti-PLA2R autoantibody concentrations allow the
assessment of disease activity: they reflect immunological rather
than clinical disease activity (proteinuria) with an increase in
antibody levels preceding a rise in proteinuria and a decrease in
antibody levels being followed by a fall in proteinuria. Determi-
nation of autoantibody concentrations also allows for predictions
regarding clinical outcome: in a prospective multicenter study
including 133 adult pMN patients with detectable anti-PLA2R
antibodies (who had not received immunosuppressive therapy at
study inclusion), anti-PLA2R antibody levels were identified as a
risk factor for not achieving remission of proteinuria (5). In this
study, immunosuppressive therapy led to a persistent reduction
of anti-PLA2R antibody levels by 81% which was accompanied
by proteinuria reduction of 39% within 3months. At the time
of study inclusion, anti-PLA2R antibody levels were significantly
lower in patients who experienced remission of proteinuria after
12months compared to patients with no remission.
Up to 40% of patients with pMN relapse after kidney trans-
plantation. This risk is particularly high if anti-PLA2R autoanti-
bodies are persistently found during the first 6months after organ
transplantation (6). Therefore, the determination of autoantibody
levels may be useful to assess the necessity and intensity of
immunosuppressive therapy after transplantation in order to
avoid relapses.
Hence, in addition to differential diagnosis of MN, the
quantification of anti-PLA2R autoantibodies by ELISA allows
assessment of disease activity and severity as well as prediction of
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disease outcome (remission, relapse) and risk of recurrence ofMN
after kidney transplantation. Moreover, it facilitates treatment
decisions and monitoring of response to treatment.
Very recently, thrombospondin type-1 domain-containing 7A
(THSD7A) was discovered as a second antigenic target in approx.
2.5–5% of patients with idiopathic MN (7). Importantly, these
autoantibodies have exclusively been found in 8–14% of anti-
PLA2R antibody-negative patients, suggesting that these patients
represent a distinct disease subgroup. No reactivity against
THSD7A was observed among healthy controls and among
patients with other proteinuric or renal autoimmune diseases.
As PLA2R, THSD7A is an N-glycosylated high molecular mass
protein expressed on the podocyte membrane and shows reactiv-
ity with serum antibodies only under non-reducing conditions.
Similar to anti-PLA2R antibodies, an association between anti-
THSD7A antibody levels and disease activity is suggested. Fur-
ther studies using THSD7A-based RC-IIFT (IgG) are currently
ongoing.
Anti-Glomerular Basement Membrane
Autoantibodies in Goodpasture’s Disease
Goodpasture’s disease is a rare organ-specific autoimmune dis-
ease that is mediated by anti-glomerular basement membrane
(anti-GBM) antibodies. Kidney involvement is characterized by
crescentic glomerulonephritis with linear immunofluorescence
staining for IgG on the GBM. The percentage of glomeru-
lar crescents is associated with poor renal outcome. Clini-
cally, Goodpasture’s disease presents with rapidly progressive
glomerulonephritis and renal failure, accompanied by pulmonary
hemorrhage that may be life-threatening. Both pulmonary and
renal involvement occur in 60–80%of the patients (8). Renalman-
ifestations alone are seen in 20–40% and are referred to as anti-
GBM glomerulonephritis. The etiology of Goodpasture’s disease
is unknown.
The diagnosis of anti-GBM disease relies on the detection of
anti-GBM antibodies (IgG) in tissues or circulation in combina-
tion with the detection of glomerulonephritis and/or alveolitis.
Anti-GBM antibodies are highly specific and sensitive markers of
the disease. The relevant antigenic target is the non-collagenous
domain 1 (NC1) of the α-3 chain of type IV collagen within
the GBM or the alveolar basal membrane. Distribution of this
molecule in the human body is limited to specific organs, such
as kidneys and lungs, thereby explaining the main manifestations
of the syndrome (9).
Anti-glomerular basement membrane antibodies are by defini-
tion present in all patients withGoodpasture’s disease. They can be
detected either by indirect immunofluorescence tests (IIFT) using
cryo-sections of primate kidney or by monospecific immunoas-
says based on the purified NC1 domain (e.g., ELISA, line assays,
microdots in IIFT). Twenty to thirty-five percent of patients with
anti-GBM antibodies also have ANCA, mostly with specificity for
myeloperoxidase (MPO). Since Goodpasture’s disease and AAV
may have the same clinical presentation, it is recommended that
anti-GBM and ANCA should be analyzed in parallel in patients
with renal disease (9) (Figure 1).
Anti-glomerular basement membrane antibodies have shown
to be crucial for early diagnosis of the disease. Clinical progression
FIGURE 1 |MPO-ANCA fluorescence pattern on the EUROIMMUN
EUROPLUSTM Granulocyte Mosaic (IgG). (A) Microscope slide with 10
reaction fields, each containing 6 biochips forming a mosaic. (B) In the
EUROPLUSTM Granulocyte Mosaic, each biochip represents a different
substrate: ethanol-fixed granulocytes [granulocytes (EOH)], formalin-fixed
granulocytes [granulocytes (HCHO)], HEp-2 cells in combination with
ethanol-fixed granulocytes [HEp-2 cells+ granulocytes (EOH)] as well as PR3,
MPO, and GBM microdots. Besides a P-ANCA pattern on ethanol-fixed
granulocytes and a granular C-ANCA pattern on formalin-fixed granulocytes,
MPO-ANCA is characterized by a positive fluorescence signal on MPO but
not on PR3 microdots. The patient sample also shows a positive fluorescence
signal on GBM microdots.
of the disease correlates with antibody concentrations, with high
concentrations of circulating anti-GBM antibodies indicating an
unfavorable prognosis.
Systemic Autoimmunity Against Ubiquitous
Antigens in Association with
Renal Inflammation
Anti-dsDNA and Anti-Nucleosome
Autoantibodies in Lupus Nephritis
Lupus nephritis is one of the most frequent and severe manifesta-
tions of SLE, contributing to end-stage renal disease and differ-
ent extrarenal complications. It can present as nephritic and/or
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nephrotic syndrome with different combinations of proteinuria,
hematuria, impaired renal function, edema, abnormal lipid pro-
file, and hypertension. Renal biopsy is an important measure
in disease management, allowing the identification of six histo-
logical classes of glomerulonephritis which have an impact on
therapeutic decisions.
Systemic lupus erythematosus and LN are characterized by the
presence of several autoantibodies directed against components
of the cell nucleus and the cytoplasm as well as against other
autoantigens. Diagnosis is based on 11 criteria according to the
American College of Rheumatology, including immunological
parameters.
Anti-nucleosome antibodies (ANuA) represent the first sero-
logical marker described in SLE. The term “nucleosome” defines
a highly organized functional subunit of chromatin which consists
of approximately two turns of dsDNA wrapped tightly around
an octamer of histones (two molecules of each H2A, H2B, H3,
and H4). Neighboring nucleosomes are joined by linker DNA,
which is associated with histone H1 located outside the nucle-
osome core. Nucleosome-specific antibodies are able to bind to
the intact nucleosome, but not its individual components (dsDNA
and histones).
Although the prevalence of ANuA in sera from SLE patients
is high, the diagnostic use of this parameter has been limited
for a long time, since sera from patients with progressive sys-
temic sclerosis (PSS) demonstrated significant positive reactions
(10–68%) with conventional ANuA test systems (first genera-
tion). These false positive reactions were eliminated in the second
generation EUROIMMUN Anti-Nucleosome ELISA (IgG) (10):
here, the antigen is based on an innovative purification protocol
using sucrose density gradient centrifugation under carefully opti-
mized NaCl conditions. This procedure results in highly purified
mononucleosomes which are free from contaminating histone
H1, non-histone proteins such as Scl-70, and chromatin DNA
fragments. Using the second generation Anti-Nucleosome ELISA,
specificity was 100%with respect to healthy blood donors and PSS
patients. In contrast, in first generation Anti-Nucleosome ELISA,
52% of sera from PSS patients cross-reacted with Scl-70 due to
impurities of the nucleosome preparation. Sensitivity was similar
in both assays.
Anti-nucleosome antibodies have been shown to be a prog-
nostic indicator for SLE with renal involvement: the prevalence
of ANuA was particularly high in severe cases of LN requiring
transplantation (79%), compared to less severe cases (18%) and
SLE without nephritis (9%) (11).
Anti-dsDNA antibodies are found in 60–90% of SLE patients
and represent the most established marker for the disease. In
order to improve the diagnostic performance of anti-dsDNA
ELISA in comparison to established test systems, an optimized
test referred to as Anti-dsDNA-NcX ELISA (IgG) was developed
by EUROIMMUN (12): this ELISA is based on a novel coating
technology and applies the highly purified mononucleosomes
used in the second generation Anti-Nucleosome ELISA as linker
substance for the immobilization of dsDNA. The specific config-
uration of the Anti-dsDNA-NcX ELISA minimizes false positive
reactions that typically occur when using conventional coating
materials such as poly--lysine and protamine sulfate. Moreover,
it ensures precise and authentic presentation of major epitopes
thus leading to superior diagnostic accuracy. At a comparable
specificity of 98.2% (based on ROC analysis), the sensitivity of
the Anti-dsDNA-NcX ELISA (IgG) (66.7%) highly exceeds that
of Farr-RIA (55.6%), Anti-Nucleosome ELISA (IgG) (55.6%),
and conventional Anti-dsDNA ELISA (IgG) (41.5%), as well as
that of IIFT using Crithidia luciliae (IgG) (28%). Comparison of
the diagnostic concordance of Anti-dsDNA-NcX ELISA, Farr-
RIA, and C. luciliae-based IIFT reveals that there is a consid-
erable number of serum samples which are solely positive in
one of the three methods with the ELISA detecting the highest
number.
Hence, the non-radioactive Anti-dsDNA-NcX ELISA is supe-
rior to Farr-RIA and C. luciliae-based IIFT in diagnosing SLE.
However, both classical methods continue to be important for the
identification of the few SLE patients who present with negative
Anti-dsDNA-NcX ELISA results.
Anti-dsDNA-NcXELISA is also suitable formonitoring disease
activity in SLE patients: in a longitudinal analysis of 20 patients
over a period of 10months, changes in Anti-dsDNA-NcX ELISA
results correlated significantly with changes in disease activity
over time (assessed by mSLEDAI 2000 score), while neither Anti-
dsDNA ELISA nor Farr-RIA did reflect these changes (12). More-
over, Anti-dsDNA-NcX ELISA might be suitable for monitoring
the course of the disease in response to treatment: preliminary
results from a longitudinal monitoring of individual LN patients
under therapy show a high correlation between Anti-dsDNA-
NcX concentrations and disease activity (assessed by BILAG-2004
score).
Anti-Neutrophil Cytoplasmic Antibodies in
Renal Vasculitis
Vasculitis associated with ANCA comprises a group of multi-
systemic diseases that affect small-to-medium-sized vessels,
resulting in a wide spectrum of organ involvement including the
kidneys and the lung. In the kidney, ANCA are predominantly
responsible for rapidly progressive glomerulonephritis which is
histologically characterized by a pauci-immune deposition pat-
tern in immunofluorescence of renal biopsy-derived tissue and
the presence of crescents in light microscopy. Renal failure is a
common and severe complication in this disease, particularly in
the elderly population.
Autoimmune vasculitis is characterized by ANCA. Unfortu-
nately, diagnosis based on clinical manifestations is complicated
because of varying and frequently non-specific initial symptoms.
Therefore, the serological determination of ANCA is an essen-
tial tool for identifying and differentiating AAV, consequently
contributing to treatment and follow-up.
A number of different methods are used to detect ANCA. The
standard technique for screening of ANCA is IIFT using ethanol-
fixed granulocytes. Two main staining patterns can be differen-
tiated: a cytoplasmic (C-ANCA) and a perinuclear (P-ANCA)
pattern. The C-ANCA pattern is mainly induced by antibodies
directed against proteinase 3 (PR3), which are typically found in
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granulomatosis with polyangiitis (GPA) but also in other AAVs.
The P-ANCA pattern mainly results from antibodies against
MPO which are associated with various AAVs, particularly
microscopic polyangiitis (MPA), eosinophilic granulomatosis
with polyangiitis (EGPA), and pauci-immune crescentic
glomerulonephritis.
According to an international consensus statement, ANCA
testing should include screening with IIFT and confirmation in
MPO- and PR3-ANCA-specific assays (13). As a multiplexing
approach, the EUROIMMUN EUROPLUS™Granulocyte Mosaic
(IgG) system combines the conventional cell substrates and single
microdots of purified PR3 andMPO as biochips in one incubation
field of a microscope slide (Figure 1) (14). Besides the simultane-
ous observation ofANCA IIFT patterns on ethanol- and formalin-
fixed granulocytes, the test system allows for exclusion of ANA
interference due to the combined HEp-2/ethanol-fixed granulo-
cyte substrate as well as for the monospecific determination of
MPO- and PR3-reactivity. This combination greatly facilitates the
interpretation of the ANCA IIFT patterns and has shown a high
concordance with a reference multi-testing algorithm [based on
the combination of IIFT with ethanol-fixed granulocytes (IgG) as
well as direct and capture ELISAs for bothMPO- and PR3-ANCA
(IgG)] (14).
Additionally, the EUROPLUS™GranulocyteMosaic can be sup-
plemented with microdots of GBM antigen in order to analyze
for potential anti-GBM antibodies (see Glomerular Basement
Membrane Autoantibodies in Goodpasture’s Disease).
A furthermajor advance inANCA testing is the recent develop-
ment of an ELISA based on a novel PR3 diagnostic antigen, which
consists of a mixture of human native (hn) PR3 and human cell-
expressed recombinant (hr) designer PR3, exhibiting modified
N- and C-terminal signal sequences as well as an inactivated
enzymatic core (15). At a defined specificity of 99%, sensitivity
of the EUROIMMUN Anti-PR3-hn-hr ELISA (IgG) is signifi-
cantly higher (95%) than sensitivity of other ELISA based only
on native antigen [Anti-PR3-hn ELISA (IgG): 80%, Anti-PR3
Capture ELISA (IgG): 77%]. In addition to its excellent diagnostic
performance, the ELISA also allows for a good predictability of
clinical relapses in patients with PR3-AAV.
Concluding Remarks
Autoantibodies can be found in several forms of nephropathies.
They can either be directed against kidney-specific autoantigens
or against ubiquitous antigens as in systemic autoimmune diseases
with renal manifestations. Recent developments in autoantibody
diagnostics in nephrology include the identification of PLA2R
and THSD7A as antigenic targets in pMN, as well as consid-
erable improvements in sensitivity, specificity, and convenience
of test systems for anti-dsDNA, ANuA, ANCA, and anti-GBM.
These advances have boosted the ease, reliability, and relevance
of autoantibody testing, aiding the diagnosis of autoimmune
nephropathies, especially in early stages. This is crucial for the
decision on interventional therapy, e.g. with immunosuppres-
sants, which can help to delay the serious and irreversible damage
that occurs with disease progression. This, in turn, may circum-
vent the need for intensive and distressing end-stage procedures
such as dialysis and transplantation – a boon for patients to the
benefit of healthcare system.
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